Cargando…

Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders

Inflammation has been implicated in the pathogenesis of Parkinson’s disease (PD). We here investigate levels of inflammatory biomarkers in cerebrospinal fluid (CSF) in PD and atypical parkinsonian disorders (APD) compared with neurologically healthy controls. We included 131 patients with PD and 27...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hall, Sara, Janelidze, Shorena, Surova, Yulia, Widner, Håkan, Zetterberg, Henrik, Hansson, Oskar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125576/ https://www.ncbi.nlm.nih.gov/pubmed/30185816 http://dx.doi.org/10.1038/s41598-018-31517-z

Ejemplares similares

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
por: Hall, Sara, et al.
Publicado: (2016)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer’s but Not Parkinson’s Disease or Dementia with Lewy Bodies
por: Wennström, Malin, et al.
Publicado: (2015)

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
por: Sjödin, Simon, et al.
Publicado: (2017)

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2020)

Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder
por: Hansson, Oskar, et al.
Publicado: (2017)

Alteration of putaminal fractional anisotropy in Parkinson’s disease: a longitudinal diffusion kurtosis imaging study
por: Surova, Yulia, et al.
Publicado: (2018)

Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson’s Disease
por: Surova, Yulia, et al.
Publicado: (2016)

Proinflammatory Cytokines Are Elevated in Serum of Patients with Multiple System Atrophy
por: Kaufman, Eli, et al.
Publicado: (2013)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions
por: Magdalinou, Nadia, et al.
Publicado: (2014)

α-synuclein−lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients
por: Paslawski, Wojciech, et al.
Publicado: (2019)

The genetic regulation of protein expression in cerebrospinal fluid
por: Hansson, Oskar, et al.
Publicado: (2022)

Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus Erythematosus
por: Zervides, Kristoffer A., et al.
Publicado: (2022)

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease
por: Schultz, Nina, et al.
Publicado: (2019)

Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotype
por: Flores Bjurström, Martin, et al.
Publicado: (2020)

DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease
por: Pereira, Joana B., et al.
Publicado: (2023)

Serum Neurofilament Light Chain as a Marker of Progression in Parkinson’s Disease: Long-Term Observation and Implications of Clinical Subtypes
por: Ygland Rödström, Emil, et al.
Publicado: (2022)

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum
por: Gobom, Johan, et al.
Publicado: (2022)

Cerebrospinal Fluid Biomarker Candidates for Parkinsonian Disorders
por: Constantinescu, Radu, et al.
Publicado: (2013)

Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in Serum
por: Lindqvist, Daniel, et al.
Publicado: (2012)

Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy
por: Surova, Yulia, et al.
Publicado: (2015)

Assessment of Global and Regional Diffusion Changes along White Matter Tracts in Parkinsonian Disorders by MR Tractography
por: Surova, Yulia, et al.
Publicado: (2013)

Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ(42) and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes
por: Vanderstichele, Hugo Marcel Johan, et al.
Publicado: (2016)

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
por: Cicognola, Claudia, et al.
Publicado: (2021)

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)
por: Vanderstichele, Hugo, et al.
Publicado: (2017)

Increased CSF biomarkers of angiogenesis in Parkinson disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2018)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders
por: Yilmaz, Aylin, et al.
Publicado: (2019)

Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease
por: Johansson, Per, et al.
Publicado: (2013)

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations
por: Lautner, Ronald, et al.
Publicado: (2017)

Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein
por: Zettergren, Anna, et al.
Publicado: (2019)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Cerebrospinal fluid pro-inflammatory cytokines differentiate parkinsonian syndromes
por: Starhof, C., et al.
Publicado: (2018)

Biosignatures for Parkinson’s Disease and Atypical Parkinsonian Disorders Patients
por: Potashkin, Judith A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_nrmhppuqd38ot218tkebkom03v